BusinessPeregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab at European Society for Medical Oncology (ESMO) 2016 CongressBy Nasdaq OMXSep 21, 2016, 12:05 PM UTC
BusinessPetLife Pharmaceuticals Continues Execution of its Vitalzul TM Business Plan with start of Proof of Concept studies; Provides UpdatesBy Nasdaq OMXSep 14, 2016, 1:10 PM UTC
BusinessKura Oncology to Participate in the 2016 Aegis Growth ConferenceBy Nasdaq OMXSep 14, 2016, 11:30 AM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2017 and Recent DevelopmentsBy Nasdaq OMXSep 8, 2016, 8:05 PM UTC
BusinessNational Comprehensive Cancer Network (NCCN) Awards Three Grants for Combination Studies of Peregrine Pharmaceuticals’ Bavituximab in Multiple CancersBy Nasdaq OMXSep 6, 2016, 12:45 PM UTC
BusinessKura Oncology to Participate in the 5th Annual Gateway ConferenceBy Nasdaq OMXSep 2, 2016, 11:30 AM UTC
BusinessPeregrine to Report Financial Results for First Quarter of Fiscal Year 2017 After Market Close on September 8, 2016By Nasdaq OMXSep 1, 2016, 8:05 PM UTC
BusinessGalectin Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment ConferenceBy Nasdaq OMXAug 31, 2016, 12:00 PM UTC
